Stock Analiz

LLY vs NVS stock comparison

ELI LILLY & Co vs. Novartis · data as of November 13, 2026

ELI LILLY & Co (LLY) has a market value of about $1.36T, Novartis (NVS) about $306.3B. Over their latest twelve months ELI LILLY & Co had revenue of $86.5B and Novartis $57.4B.

On our five checks ELI LILLY & Co scores higher: 3.4 out of 5 (good) against 2.0 (weak).

By area, the stronger company is ELI LILLY & Co on future growth; ELI LILLY & Co on track record; ELI LILLY & Co on shareholder returns.

Novartis is cheaper on earnings (P/E 30.7 vs. 46.9), while ELI LILLY & Co grew revenue faster over five years (21.6% vs. 2.3% a year).

ELI LILLY & Co leads on 14 of the compared lines and Novartis on 9.

Side by side

LLYNVS
Size and price
Market cap$1.36T$306.3B
Share price$1,443.50$160.50
Score
Overall score (of 5)3.42.0
Value00
Future growth50
Track record54
Financial health33
Shareholder returns43
Valuation
P/E (TTM)46.930.7
Forward P/E30.417.0
Price / free cash flow69.121.9
Price / sales15.75.3
EV / EBITDA37.114.4
PEG1.702.02
DCF value vs. price−37%−9%
Business
Revenue$86.5B$57.4B
Net income$27.6B$10.0B
Free cash flow$19.7B$14.0B
Net margin31.9%17.5%
Gross margin (5-yr avg.)78.9%76.4%
ROIC (5-yr avg.)22.9%14.1%
Growth
Revenue growth (1 yr)44.7%8.4%
Revenue growth (5 yrs, per year)21.6%2.3%
EPS growth (5 yrs, per year)27.6%15.2%
Balance sheet and payouts
Net cash (cash minus debt)-$44.6B-$39.3B
Dividend yield0.48%2.95%
Shareholder yield0.8%6.0%
Analysts
Upside to average target+1%−2%
Consensus ratingBuyHold

Highlighted = the better figure on that line. Revenue, net income and free cash flow: LLY TTM to September 30, 2026, NVS TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, ELI LILLY & Co or Novartis?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) ELI LILLY & Co scores 3.4 out of 5 and Novartis 2.0; the table shows where each one is stronger.

Is ELI LILLY & Co cheaper than Novartis?

On trailing earnings, Novartis trades at a P/E of 30.7 and ELI LILLY & Co at 46.9, so Novartis is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, ELI LILLY & Co or Novartis?

Over five years ELI LILLY & Co grew revenue about 21.6% a year and Novartis about 2.3% a year.

Which pays a higher dividend?

ELI LILLY & Co yields 0.48% and Novartis 2.95%.

Full ELI LILLY & Co analysis → Full Novartis analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.